Biotech · Private company
Mural Oncology, Inc
Track this companyFree. Adds Mural Oncology, Inc to your Dealase workspace and tells you when its record changes.
Clinical trials61 recruiting or active
Pipeline programs17From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline17
- NemvaleukinPhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Nemvaleukin and Pembrolizumab CombinationPhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PaclitaxelPhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- Pegylated Liposomal Doxorubicin (PLD)Phase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- TopotecanPhase 3 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 4230Phase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- ALKS 4230 + pembrolizumabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Nemvaleukin alfaPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Nemvaleukin AlfaPhase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- Nemvaleukin Alfa IntravenousPhase 2 · Cutaneous MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Nemvaleukin Alfa Intravenous Less Frequent DosingPhase 2 · Cutaneous MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- Nemvaleukin Alfa SubcutaneousPhase 2 · Cutaneous MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Squamous Cell Carcinoma of Head and NeckClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Cutaneous MelanomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)PHASE3 · TERMINATED · started Jan 10, 2022ClinicalTrials.gov NCT05092360 · fetched Nov 12, 2026
- Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6PHASE2 · TERMINATED · started Sep 27, 2021ClinicalTrials.gov NCT04830124 · fetched Nov 12, 2026
- Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Sep 30, 2020ClinicalTrials.gov NCT04592653 · fetched Nov 12, 2026
- A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck CancerPHASE2 · COMPLETED · started Feb 5, 2020ClinicalTrials.gov NCT04144517 · fetched Nov 12, 2026
- A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)PHASE1_PHASE2 · COMPLETED · started Feb 26, 2019ClinicalTrials.gov NCT03861793 · fetched Nov 12, 2026
- A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid TumorsPHASE1_PHASE2 · COMPLETED · started Sep 14, 2016ClinicalTrials.gov NCT02799095 · fetched Nov 12, 2026